These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36762756)

  • 1. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.
    Nørgaard M; Bjerre MT; Fredsøe J; Vang S; Jensen JB; De Laere B; Grönberg H; Borre M; Lindberg J; Sørensen KD
    Clin Chem; 2023 Apr; 69(4):386-398. PubMed ID: 36762756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    Sumanasuriya S; Seed G; Parr H; Christova R; Pope L; Bertan C; Bianchini D; Rescigno P; Figueiredo I; Goodall J; Fowler G; Flohr P; Mehra N; Neeb A; Rekowski J; Eisenberger M; Sartor O; Oudard S; Geffriaud-Ricouard C; Ozatilgan A; Chadjaa M; Macé S; Lord C; Baxter J; Pettitt S; Lambros M; Sharp A; Mateo J; Carreira S; Yuan W; de Bono JS
    Eur Urol; 2021 Aug; 80(2):243-253. PubMed ID: 34103179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
    Tolmeijer SH; Boerrigter E; Sumiyoshi T; Kwan EM; Ng SWS; Annala M; Donnellan G; Herberts C; Benoist GE; Hamberg P; Somford DM; van Oort IM; Schalken JA; Mehra N; van Erp NP; Wyatt AW
    Clin Cancer Res; 2023 Aug; 29(15):2835-2844. PubMed ID: 36996325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
    Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
    Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
    Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.
    Sweeney CJ; Petry R; Xu C; Childress M; He J; Fabrizio D; Gjoerup O; Morley S; Catlett T; Assaf ZJ; Yuen K; Wongchenko M; Shah K; Gupta P; Hegde P; Pasquina LW; Mariathasan S; Graf RP; Powles T
    Clin Cancer Res; 2024 Sep; 30(18):4115-4122. PubMed ID: 38990098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
    Du M; Tian Y; Tan W; Wang L; Wang L; Kilari D; Huang CC; Wang L; Kohli M
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):705-713. PubMed ID: 32203070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
    Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
    Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
    Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
    J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
    Annala M; Fu S; Bacon JVW; Sipola J; Iqbal N; Ferrario C; Ong M; Wadhwa D; Hotte SJ; Lo G; Tran B; Wood LA; Gingerich JR; North SA; Pezaro CJ; Ruether JD; Sridhar SS; Kallio HML; Khalaf DJ; Wong A; Beja K; Schönlau E; Taavitsainen S; Nykter M; Vandekerkhove G; Azad AA; Wyatt AW; Chi KN
    Ann Oncol; 2021 Jul; 32(7):896-905. PubMed ID: 33836265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
    Conteduca V; Casadei C; Scarpi E; Brighi N; Schepisi G; Lolli C; Gurioli G; Toma I; Poti G; Farolfi A; De Giorgi U
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
    Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
    Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.